Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;8(6):2085-2088.e10.
doi: 10.1016/j.jaip.2020.01.047. Epub 2020 Feb 4.

Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients

Sherezade Moñino-Romero  1 , Leticia de Las Vecillas  2 , Leila A Alenazy  3 , Marina Labella  4 , Zsolt Szépfalusi  5 , Edda Fiebiger  6 , Mariana C Castells  4
Affiliations

Soluble FcεRI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients

Sherezade Moñino-Romero et al. J Allergy Clin Immunol Pract. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Baseline sFcεRI levels as a biomarker for risk of IgE-mediated reactions during DS. Outline of the in vivo DS protocol of 3 bags/ 12 steps (A). Levels of total sFcεRI, total IgE, and tryptase before (black squares) and after (blue circles) DS. Patients (n = 5) with sFcεRI levels >2 ng/mL (B) and patients (n = 9) with sFcεRI levels <2 ng/mL (C) are represented. Levels of total sFcεRI (D) and tryptase (E) before and after DS. Patients (n = 5) with sFcεRI levels >2 ng/mL (white bar) and patients (n = 9) with sFcεRI levels <2 ng/mL (orange bar) are represented (D) as box and whisker graphs (minimum to maximum). A paired t-test or a Mann-Whitney test was performed, where *P < .05, ***P < .001. DS, Desensitization; sFcεRI, soluble FcεRI.
FIGURE 2.
FIGURE 2.
Rapid desensitization (DS) of mast cells (MCs) inhibits release of sFcεRI and it requires cumulative doses. Outline of the in vitro rapid DS protocol (A). A total of 1 × 106/mL MCs (humanized murine bone marrow–ederived MCs) or MuKO (mFcεRIα−/−) cells were loaded overnight with up to 10% allergic human serum in 200 μL (B, C). Percentage of β-hexosaminidase release (B) and total sFcεRI levels (C) were measured after DS with 0.5 μg/mL anti-hIgE. Razin Medium was used as control. A total of 1 × 106/mL MCs were loaded overnight with 0.5 μg/mL anti-NP cIgE (D, E). Total sFcεRI levels were measured after a single-dose challenge or cumulative doses (10 pg/mL to 10 ng/mL NP-BSA) for 10 or 110 minutes. A single challenge with 10 ng/mL NP-BSA (Act) or 10 ng/mL BSA (Neg) was used as a control. Data represent mean ± SEM of n = 3–8 independent experiments. A 1-way ANOVA test plus Tukey’s multiple correction (B-E) was performed, where */δP < .05, **/δδP < .01, and ***P < .001 compared with Neg (B, C) or Act (D, E). δRepresents statistics between conditions in white bars (D). ANOVA, Analysis of variance; BSA, bovine serum albumin; nd, not detected; NP-BSA, 4-hydroxy-3-nitrophenylacetyl bovine serum albumin; SEM, standard error of the mean; sFcεRI, soluble FcεRI.
See this image and copyright information in PMC

References

    1. Castells M Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol 2017;8:1472. - PMC - PubMed
    1. Otani IM, Wong J, Banerji A. Platinum chemotherapy hypersensitivity: prevalence and management. Immunol Allergy Clin North Am 2017;37:663–77. - PubMed
    1. Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol 2018;142:159–170. e2. - PubMed
    1. Deak PE, Kim B, Adnan A, Labella M, De Las Vecillas L, Castells M, et al. Nanoallergen platform for detection of platin drug allergies. J Allergy Clin Immunol 2019;143:1957–1960. e12. - PMC - PubMed
    1. Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, et al. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. J Cancer Res Clin Oncol 2018;144:2449–56. - PMC - PubMed

Publication types